NCT00780676View on ClinicalTrials.gov

Personalized Treatment Selection for Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Breast Cancer
Interventions
DRUG

Dasatinib

100 mg tablet by mouth daily

DRUG

AZD6244

75 mg by mouth twice daily.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER